Cargando…

Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges

Retroperitoneal fibrosis (RPF) is a rare disorder consisting of idiopathic and various secondary forms and characterized by chronic inflammatory infiltrates and marked fibrosis in the retroperitoneal space. In idiopathic RPF (IRPF), 35–60% of cases have been reported to be IgG4-related RPF, the retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizushima, Ichiro, Kawano, Mitsuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328390/
https://www.ncbi.nlm.nih.gov/pubmed/34349543
http://dx.doi.org/10.2147/IJNRD.S239160
_version_ 1783732302432436224
author Mizushima, Ichiro
Kawano, Mitsuhiro
author_facet Mizushima, Ichiro
Kawano, Mitsuhiro
author_sort Mizushima, Ichiro
collection PubMed
description Retroperitoneal fibrosis (RPF) is a rare disorder consisting of idiopathic and various secondary forms and characterized by chronic inflammatory infiltrates and marked fibrosis in the retroperitoneal space. In idiopathic RPF (IRPF), 35–60% of cases have been reported to be IgG4-related RPF, the retroperitoneal lesions of IgG4-related disease (IgG4-RD). IRPF can frequently lead to renal insufficiency mediated by urinary tract obstruction and hydronephrosis irrespective of being IgG4-related or not. Clinical pictures, laboratory and imaging findings, and location of the urinary tract obstruction are generally similar in IgG4-related and non-IgG4-related IRPF although multiple organ involvement and serum IgG4 elevation may be characteristic of the IgG4-related forms. Periaortic/periarterial lesions are the most frequent cause of renal insufficiency. Although the response to glucocorticoids is generally good, relapse does occur in a considerable proportion of patients, and may require an additional immunosuppressive agent and/or urological intervention in cases with multiple relapses or refractory obstructive uropathy. In general, the prognosis of patients with IRPF is good, but careful attention needs to be paid to chronic kidney disease as a major complication and rupture of the affected aorta/artery as a life-threatening one. Further studies are necessary to better understand the pathogenesis of the disease and to establish the optimal diagnostic and therapeutic strategies for it.
format Online
Article
Text
id pubmed-8328390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83283902021-08-03 Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges Mizushima, Ichiro Kawano, Mitsuhiro Int J Nephrol Renovasc Dis Review Retroperitoneal fibrosis (RPF) is a rare disorder consisting of idiopathic and various secondary forms and characterized by chronic inflammatory infiltrates and marked fibrosis in the retroperitoneal space. In idiopathic RPF (IRPF), 35–60% of cases have been reported to be IgG4-related RPF, the retroperitoneal lesions of IgG4-related disease (IgG4-RD). IRPF can frequently lead to renal insufficiency mediated by urinary tract obstruction and hydronephrosis irrespective of being IgG4-related or not. Clinical pictures, laboratory and imaging findings, and location of the urinary tract obstruction are generally similar in IgG4-related and non-IgG4-related IRPF although multiple organ involvement and serum IgG4 elevation may be characteristic of the IgG4-related forms. Periaortic/periarterial lesions are the most frequent cause of renal insufficiency. Although the response to glucocorticoids is generally good, relapse does occur in a considerable proportion of patients, and may require an additional immunosuppressive agent and/or urological intervention in cases with multiple relapses or refractory obstructive uropathy. In general, the prognosis of patients with IRPF is good, but careful attention needs to be paid to chronic kidney disease as a major complication and rupture of the affected aorta/artery as a life-threatening one. Further studies are necessary to better understand the pathogenesis of the disease and to establish the optimal diagnostic and therapeutic strategies for it. Dove 2021-07-29 /pmc/articles/PMC8328390/ /pubmed/34349543 http://dx.doi.org/10.2147/IJNRD.S239160 Text en © 2021 Mizushima and Kawano. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mizushima, Ichiro
Kawano, Mitsuhiro
Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges
title Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges
title_full Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges
title_fullStr Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges
title_full_unstemmed Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges
title_short Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges
title_sort renal involvement in retroperitoneal fibrosis: prevalence, impact and management challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328390/
https://www.ncbi.nlm.nih.gov/pubmed/34349543
http://dx.doi.org/10.2147/IJNRD.S239160
work_keys_str_mv AT mizushimaichiro renalinvolvementinretroperitonealfibrosisprevalenceimpactandmanagementchallenges
AT kawanomitsuhiro renalinvolvementinretroperitonealfibrosisprevalenceimpactandmanagementchallenges